Crohn’s disease (CD), a chronic inflammatory condition of the intestinal tract, is affecting people globally. Experts have long suspected that CD represents a collection of related but slightly different disorders.
This is important because patients with subtype 1, unlike subtype 2, often do not respond well to medications and develop strictures – extreme narrowing of the gut tube, requiring surgery once it develops. Markers like miR-31 could be useful in the future for clinicians to predict whether a patient should pursue pre-emptive surgery before the condition worsens.
“We are not at the point at which we are able to perform personalized medicine on this, but at the very least we think it can lead to better clinical trial designs,” said Praveen Sethupathy, senior co-author of the study.
In the study, the researchers also used a state-of-the-art artificial gut, called an intestinal organoid, which allowed them to culture human biopsy samples while retaining the basic physiology that exists inside a human.
The researchers also used cutting-edge genomic techniques to track the abundance of different molecules in the colon tissue of more than 150 pediatric and adult patients. MicroRNAs control the extent to which a target gene is turned on. They function as negative dials – the greater the abundance of a microRNA, the more a target gene will be suppressed. Data from genomic sequencing technology allowed the researchers to make their miR-31 discovery.
No comments:
Post a Comment